Drug Profile
ASP 6432
Alternative Names: ASP6432Latest Information Update: 21 May 2014
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 12 May 2014 Discontinued - Phase-I for Benign prostatic hyperplasia in Japan (unspecified route)
- 01 Aug 2012 Phase-I clinical trials in Benign prostatic hyperplasia in Japan (unspecified route)